Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 144 No. 3334 (2014)

Proteostasis: Bad news and good news from the endoplasmic reticulum

  • Julia Noack
  • Giorgia Brambilla Pisoni
  • Maurizio Molinari
DOI
https://doi.org/10.4414/smw.2014.14001
Cite this as:
Swiss Med Wkly. 2014;144:w14001
Published
10.08.2014

Summary

The endoplasmic reticulum (ER) is an intracellular compartment dedicated to the synthesis and maturation of secretory and membrane proteins, totalling about 30% of the total eukaryotic cells proteome. The capacity to produce correctly folded polypeptides and to transport them to their correct intra- or extracellular destinations relies on proteostasis networks that regulate and balance the activity of protein folding, quality control, transport and degradation machineries. Nutrient and environmental changes, pathogen infection aging and, more relevant for the topics discussed in this review, mutations that impair attainment of the correct 3D structure of nascent polypeptide chains may compromise the activity of the proteostasis networks with devastating consequences on cells, organs and organisms’ homeostasis. Here we present a review of mechanisms regulating folding and quality control of proteins expressed in the ER, and we describe the protein degradation and the ER stress pathways activated by the expression of misfolded proteins in the ER lumen. Finally, we highlight select examples of proteopathies (also known as conformational disorders or protein misfolding diseases) caused by protein misfolding in the ER and/or affecting cellular proteostasis and therapeutic interventions that might alleviate or cure the disease symptoms.

References

  1. Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem. 2004;73:1019–49.
  2. Kelleher DJ, Gilmore R. An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology. 2006;16(4):47R-62R.
  3. Caramelo JJ, Parodi AJ. How sugars convey information on protein conformation in the endoplasmic reticulum. Sem Cell Dev Biol. 2007;18(6):732–42.
  4. Hebert DN, Molinari M. Flagging and docking: dual roles for N-glycans in protein quality control and cellular proteostasis. Trends Biochem Sci. 2012;37(10):404–10.
  5. Molinari M. N-glycan structure dictates extension of protein folding or onset of disposal. Nat Chem Biol. 2007;3(6):313–20.
  6. Schallus T, Jaeckh C, Feher K, Palma AS, Liu Y, Simpson JC, et al. Malectin: a novel carbohydrate-binding protein of the endoplasmic reticulum and a candidate player in the early steps of protein N-glycosylation. Mol Biol Cell. 2008;19(8):3404–14.
  7. Galli C, Bernasconi R, Solda T, Calanca V, Molinari M. Malectin participates in a backup glycoprotein quality control pathway in the mammalian ER. PLoS One. 2011;6(1):e16304.
  8. Aebi M, Bernasconi R, Clerc S, Molinari M. N-glycan structures: recognition and processing in the ER. Trends Biochem Sci. 2010;35(2):74–82.
  9. Hendershot LM. The ER function BiP is a master regulator of ER function. Mt Sinai J Med. New York. 2004;71(5):289–97.
  10. Jansen G, Maattanen P, Denisov AY, Scarffe L, Schade B, Balghi H, et al. An interaction map of endoplasmic reticulum chaperones and foldases. Molecular & cellular proteomics: MCP. 2012;11(9):710–23.
  11. Hatahet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. Antioxidants & redox signaling. 2009;11(11):2807–50.
  12. Hammond C, Braakman I, Helenius A. Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proceed Nat Acad Sci U S A. 1994;91(3):913–7.
  13. Sousa MC, Ferrero-Garcia MA, Parodi AJ. Recognition of the oligosaccharide and protein moieties of glycoproteins by the UDP-Glc:glycoprotein glucosyltransferase. Biochemistry. 1992;31(1):97–105.
  14. Solda T, Galli C, Kaufman RJ, Molinari M. Substrate-specific requirements for UGT1–dependent release from calnexin. Mol Cell. 2007;27(2):238–49.
  15. Olivari S, Molinari M. Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in degradation of folding-defective glycoproteins. FEBS letters. 2007;581(19):3658–64.
  16. Olzmann JA, Kopito RR, Christianson JC. The mammalian endoplasmic reticulum-associated degradation system. Cold Spring Harb Perspect Biol. 2013;5(9).
  17. Molinari M, Galli C, Piccaluga V, Pieren M, Paganetti P. Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. J Cell Biol. 2002;158(2):247–57.
  18. Tsai B, Rodighiero C, Lencer WI, Rapoport TA. Protein disulfide isomerase acts as a redox-dependent chaperone to unfold cholera toxin. Cell. 2001;104(6):937–48.
  19. Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M. Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PloS one. 2010;5(9).
  20. Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol. 2012;197(7):857–67.
  21. Bernasconi R, Molinari M. ERAD and ERAD tuning: disposal of cargo and of ERAD regulators from the mammalian ER. Curr Opin Cell Biol. 2011;23(2):176–83.
  22. Kamhi-Nesher S, Shenkman M, Tolchinsky S, Fromm SV, Ehrlich R, Lederkremer GZ. A novel quality control compartment derived from the endoplasmic reticulum. Mol Biol Cell. 2001;12(6):1711–23.
  23. Ben-Gedalya T, Lyakhovetsky R, Yedidia Y, Bejerano-Sagie M, Kogan NM, Karpuj MV, et al. Cyclosporin-A-induced prion protein aggresomes are dynamic quality-control cellular compartments. J Cell Sci. 2011;124(Pt 11):1891–902.
  24. Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, et al. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med. 2007;13(12):1504–9.
  25. Merulla J, Fasana E, Solda T, Molinari M. Specificity and regulation of the endoplasmic reticulum-associated degradation machinery. Traffic. 2013;14(7):767–77.
  26. Leitman J, Ron E, Ogen-Shtern N, Lederkremer GZ. Compartmentalization of ER quality control and ERAD factors. DNA Cell biol. 2013;32(1):2–7.
  27. Nakatsukasa K, Brodsky JL, Kamura T. Astalled retrotranslocation complex reveals physical linkage between substrate recognition and proteosomal degradation during ERAD. Mol Biol Cell. 2013;24811):1765–1775.
  28. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081–6.
  29. Rutkowski DT, Kaufman RJ. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci. 2007;32(10):469–76.
  30. Hussain SG, Ramaiah KV. Reduced eIF2alpha phosphorylation and increased proapoptotic proteins in aging. Biochem Biophys Res Commun. 2007;355(2):365–70.
  31. Paz Gavilan M, Vela J, Castano A, Ramos B, del Rio JC, Vitorica J, et al. Cellular environment facilitates protein accumulation in aged rat hippocampus. Neurobiol Aging. 2006;27(7):973–82.
  32. Naidoo N, Ferber M, Master M, Zhu Y, Pack AI. Aging impairs the unfolded protein response to sleep deprivation and leads to proapoptotic signaling. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2008;28(26):6539–48.
  33. Taylor RC, Dillin A. XBP-1 is a cell-nonautonomous regulator of stress resistance and longevity. Cell. 2013;153(7):1435–47.
  34. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000;404(6779):770–4.
  35. Vabulas RM, Hartl FU. Protein synthesis upon acute nutrient restriction relies on proteasome function. Science. 2005;310(5756):1960–3.
  36. Bernasconi R, Pertel T, Luban J, Molinari M. A dual task for the Xbp1–responsive OS-9 variants in the mammalian endoplasmic reticulum: inhibiting secretion of misfolded protein conformers and enhancing their disposal. J Biol Chem. 2008;283(24):16446–54.
  37. Kopito RR. Biosynthesis and degradation of CFTR. Physiological reviews. 1999;79(1 Suppl):S167–73.
  38. Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiological reviews. 2007;87(4):1377–408.
  39. Wilke CO, Drummond DA. Signatures of protein biophysics in coding sequence evolution. Curr Opin Struct Biol. 2010;20(3):385–9.
  40. Silverman GA, Pak SC, Perlmutter DH. Disorders of protein misfolding: alpha-1–antitrypsin deficiency as prototype. J Pediatr. 2013;163(2):320–6.
  41. Ledford H. Drug bests cystic-fibrosis mutation. Nature. 2012;482(7384):145.
  42. Cant N, Pollock N, Ford RC. CFTR structure and cystic fibrosis. Int J Biochem Cell Biol. 2014 Feb 15.
  43. Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol. 2011;3(2).
  44. Oberdorf J, Pitonzo D, Skach WR. An energy-dependent maturation step is required for release of the cystic fibrosis transmembrane conductance regulator from early endoplasmic reticulum biosynthetic machinery. J Biol Chem. 2005;280(46):38193–202.
  45. Corris PA. Lung transplantation for cystic fibrosis and bronchiectasis. Sem Respir Crit Care Med. 2013;34(3):297–304.
  46. Lindquist SL, Kelly JW. Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol. 2011;3(12).
  47. Gieselmann V. Lysosomal storage diseases. Biochim Biophys Acta. 1995;1270(2–3):103–36.
  48. Suzuki Y. Chaperone therapy update: Fabry disease, GM1–gangliosidosis and Gaucher disease. Brain Dev. 2013;35(6):515–23.
  49. Xu YH, Xu K, Sun Y, Liou B, Quinn B, Li RH, et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Human Mol Genet. 2014 Mar 18.
  50. Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Human mutation. 2008;29(5):567–83.
  51. Celtikci B, Topcu M, Ozkara HA. Two novel alpha-galactosidase A mutations causing Fabry disease: A missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man. Clin Biochem. 2011;44(10–11):809–12.
  52. Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol. 2006;83(2):96–102.
  53. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 1997;8(Suppl 2):S3–14.
  54. Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27(2):336–49.
  55. Tenreiro S, Eckermann K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci. 2014;7:42.
  56. Drouet B, Pincon-Raymond M, Chambaz J, Pillot T. Molecular basis of Alzheimer’s disease. Cellular and molecular life sciences: CMLS. 2000;57(5):705–15.
  57. Lee G, Leugers CJ. Tau and tauopathies. Prog Mol Biol Transl Sci. 2012;107:263–93.
  58. Goldberg MS, Lansbury PT, Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson’s disease? Nat Cell Biol. 2000;2(7):E115–9.
  59. Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH. The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol. 2012;124(3):339–52.
  60. Schwenk BM, Edbauer D. The ER under rapid fire. EMBO J. 2014;33(11):1195–7.
  61. Ryno LM, Wiseman RL, Kelly JW. Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Curr Opin Chem Biol. 2013;17(3):346–52.
  62. Leahy JL, Cefalu WT. Insulin physiology and therapy. Preface. Endocrinol Metab Clin North Am. 2012;41(1):xiii–xiv.
  63. Brady RO. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res. 2006;9(2):237–44.
  64. Giugliani R. Mucopolysacccharidoses: From understanding to treatment, a century of discoveries. Genet Mol Biol. 2012;35(4 (suppl)):924–31.
  65. Noh H, Lee JI. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014 Feb 25.
  66. Roth SD, Schuttrumpf J, Milanov P, Abriss D, Ungerer C, Quade-Lyssy P, et al. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. PloS one. 2012;7(9):e44505.
  67. Valayannopoulos V. Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression. Handb Clin Neurol. 2013;113:1851–7.
  68. Mullard A. Gene therapies advance towards finish line. Nat Rev Drug Discov. 2011;10(10):719–20.
  69. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–65.
  70. Cancio MI, Reiss UM, Nathwani AC, Davidoff AM, Gray JT. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet. 2013;6:91–101.
  71. Ferreira V, Petry H, Salmon F. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. Front Immunol. 2014;5:82.
  72. Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies JC, Gill DR, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax. 2013;68(11):1075–7.
  73. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137–40.
  74. de Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, de Sousa M. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem. 2007;282(38):27905–12.
  75. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4–phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Investigative ophthalmology & visual science. 2007;48(4):1683–90.
  76. Sauer T, Patel M, Chan CC, Tuo J. Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration. Expert Rev Ophthalmol. 2008;3(1):29–42.
  77. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2013;1(2):158–63.
  78. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science. 2010;329(5993):805–10.
  79. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, et al. Mechanism-based corrector combination restores DeltaF508–CFTR folding and function. Nat Chem Biol. 2013;9(7):444–54.
  80. Said G, Grippon S, Kirkpatrick P. Tafamidis. Nat Rev Drug Discov. 2012;11(3):185–6.
  81. Dejeans N, Manie S, Hetz C, Bard F, Hupp T, Agostinis P, et al. Addicted to secrete – novel concepts and targets in cancer therapy. Trends Mol Med. 2014 Jan 20.
  82. Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeliger MA, et al. Divergent allosteric control of the IRE1alpha endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012;8(12):982–9.
  83. Kudo T, Kanemoto S, Hara H, Morimoto N, Morihara T, Kimura R, et al. A molecular chaperone inducer protects neurons from ER stress. Cell Death Differ. 2008;15(2):364–75.
  84. Chiang WC, Hiramatsu N, Messah C, Kroeger H, Lin JH. Selective activation of ATF6 and PERK endoplasmic reticulum stress signaling pathways prevent mutant rhodopsin accumulation. Investigative ophthalmology & visual science. 2012;53(11):7159–66.
  85. Chiang WC, Messah C, Lin JH. IRE1 directs proteasomal and lysosomal degradation of misfolded rhodopsin. Mol Biol Cell. 2012;23(5):758–70.
  86. Smith SE, Granell S, Salcedo-Sicilia L, Baldini G, Egea G, Teckman JH, et al. Activating transcription factor 6 limits intracellular accumulation of mutant alpha(1)-antitrypsin Z and mitochondrial damage in hepatoma cells. J Biol Chem. 2011;286(48):41563–77.
  87. Tsaytler P, Harding HP, Ron D, Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 2011;332(6025):91–4.
  88. Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, et al. Suppression of eIF2alpha kinases alleviates Alzheimer’s disease-related plasticity and memory deficits. Nat Neurosci. 2013;16(9):1299–305.
  89. Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Science translational medicine. 2013;5(206):206ra138.